Reports
Global Biologics Market Analysis, Share, Trends, Forecast: By Source: Microbial Source, Mammalian Source, Others; By Product Type: Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi and Molecular Therapy, Others; By Manufacturing; By Disease Category; Regional Analysis; Competitive Landscape; 2024-2032
Global Biologics Market Outlook
The global biologics market is expected to grow in the forecast period of 2024-2032 at a CAGR of 4.1% to reach approximately USD 528.15 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Microbial Sources to Witness a Rapid Growth Over the Forecast Period
Regionally, North America holds a significant market share owing to the presence of several major companies and subsequent heavy investments in the R&D sector. Meanwhile, a noteworthy share of key players in the Asia Pacific is likely to drive the market growth in the coming years. Since a major portion of the product range has its source in microbial expressions system, the largest share of the market is occupied by microbial sources. These are extensively used during the process of treatment of several chronic diseases depending on the type of monoclonal antibodies. Moreover, products used in cancer treatment predominantly in the oncology segment generate a significant revenue share for the monoclonal antibodies (MABs) segment.
Biologics: Market Segmentation
Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of their components, such as blood, cells, genes, tissues, allergens, and recombinant proteins. They control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
On the basis of source, the market can be segmented into:
- Microbial Source
- Mammalian Source
- Others
The market can be broadly categorised based on its product type into:
- Monoclonal Antibodies
- Murine MABs
- Chimeric MABs
- Humanised MABs
- Human MABs
- Others
- Vaccines
- Recombinant Proteins
- Antisense, RNAi and Molecular Therapy
- Others
Based on manufacturing, the market can be segmented into:
- Outsourced
- In-house
The market for biologics based on disease category is divided into:
- Oncology
- Infectious Disease
- Immunological Disorders
- Cardiovascular disorders
- Hematologic Disorders
- Others
The regional markets for biologics include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Incidences of Chronic Diseases Likely to Boost Growth for Biologics Industry
The global market for biologics is being driven by the escalating incidences and diagnosis of chronic diseases that require improved diagnostics and treatment drugs. The evident increase in the number of cancer patients and subsequent deaths worldwide, year after year, is creating a need to modify therapies and introduce drugs, which can enhance the immune system and destroy cancer cells at the earliest possible stage. Scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biologics products.
Furthermore, government authorities, taking initiatives to promote the healthcare sector to ensure the availability of biologics, are expected to offer an additional boost to the market growth. Moreover, research and development (R&D) activities undertaken by several major companies are anticipated to improve the efficacy of oral products for rheumatoid arthritis and Crohn’s diseases.
Key Industry Players in the Global Biologics Market
The report presents a detailed analysis of the following key players in the global biologics market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Samsung Biologics
- Amgen Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Merck & Co., Inc.
- Precision Biologics, Inc.
- F. Hoffmann-La Roche AG
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Source, Product Type, Manufacturing, Disease Category, Region |
| Breakup by Source | Microbial Source, Mammalian Source, Others |
| Breakup by Product Type | Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi and Molecular Therapy, Others |
| Breakup by Manufacturing | Outsourced, In-house |
| Breakup by Disease Category | Oncology, Infectious Disease, Immunological Disorders, Cardiovascular disorders, Hematologic Disorders, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Trade Data Analysis | Major Importing Countries by Value and Volume, Major Exporting Countries by Value and Volume |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | Samsung Biologics, Amgen Inc., Novo Nordisk A/S, Pfizer Inc., Merck & Co., Inc., Precision Biologics, Inc., F. Hoffmann-La Roche AG, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Biologics Market Analysis
8.1 Key Industry Highlights
8.2 Global Biologics Historical Market (2018-2023)
8.3 Global Biologics Market Forecast (2024-2032)
8.4 Global Biologics Market by Source
8.4.1 Microbial Source
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Mammalian Source
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Others
8.5 Global Biologics Market by Product Type
8.5.1 Monoclonal Antibodies
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.1.2.1 Murine MABs
8.5.1.2.2 Chimeric MABs
8.5.1.2.3 Humanised MABs
8.5.1.2.4 Human MABs
8.5.1.2.5 Others
8.5.2 Vaccines
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Recombinant Proteins
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Antisense, RNAi and Molecular Therapy
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Others
8.6 Global Biologics Market by Manufacturing
8.6.1 Outsourced
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 In-house
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.7 Global Biologics Market by Disease Category
8.7.1 Oncology
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Infectious Disease
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Immunological Disorders
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Cardiovascular disorders
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Hematologic Disorders
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
8.7.6 Others
8.8 Global Biologics Market by Region
8.8.1 North America
8.8.1.1 Historical Trend (2017-2021)
8.8.1.2 Forecast Trend (2022-2027)
8.8.2 Europe
8.8.2.1 Historical Trend (2017-2021)
8.8.2.2 Forecast Trend (2022-2027)
8.8.3 Asia Pacific
8.8.3.1 Historical Trend (2017-2021)
8.8.3.2 Forecast Trend (2022-2027)
8.8.4 Latin America
8.8.4.1 Historical Trend (2017-2021)
8.8.4.2 Forecast Trend (2022-2027)
8.8.5 Middle East and Africa
8.8.5.1 Historical Trend (2017-2021)
8.8.5.2 Forecast Trend (2022-2027)
9 North America Biologics Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.2 Canada
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
10 Europe Biologics Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2017-2021)
10.1.2 Forecast Trend (2022-2027)
10.2 Germany
10.2.1 Historical Trend (2017-2021)
10.2.2 Forecast Trend (2022-2027)
10.3 France
10.3.1 Historical Trend (2017-2021)
10.3.2 Forecast Trend (2022-2027)
10.4 Italy
10.4.1 Historical Trend (2017-2021)
10.4.2 Forecast Trend (2022-2027)
10.5 Others
11 Asia Pacific Biologics Market Analysis
11.1 China
11.1.1 Historical Trend (2017-2021)
11.1.2 Forecast Trend (2022-2027)
11.2 Japan
11.2.1 Historical Trend (2017-2021)
11.2.2 Forecast Trend (2022-2027)
11.3 India
11.3.1 Historical Trend (2017-2021)
11.3.2 Forecast Trend (2022-2027)
11.4 ASEAN
11.4.1 Historical Trend (2017-2021)
11.4.2 Forecast Trend (2022-2027)
11.5 Australia
11.5.1 Historical Trend (2017-2021)
11.5.2 Forecast Trend (2022-2027)
11.6 Others
12 Latin America Biologics Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2017-2021)
12.1.2 Forecast Trend (2022-2027)
12.2 Argentina
12.2.1 Historical Trend (2017-2021)
12.2.2 Forecast Trend (2022-2027)
12.3 Mexico
12.3.1 Historical Trend (2017-2021)
12.3.2 Forecast Trend (2022-2027)
12.4 Others
13 Middle East and Africa Biologics Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2017-2021)
13.1.2 Forecast Trend (2022-2027)
13.2 United Arab Emirates
13.2.1 Historical Trend (2017-2021)
13.2.2 Forecast Trend (2022-2027)
13.3 Nigeria
13.3.1 Historical Trend (2017-2021)
13.3.2 Forecast Trend (2022-2027)
13.4 South Africa
13.4.1 Historical Trend (2017-2021)
13.4.2 Forecast Trend (2022-2027)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Trade Data Analysis (HS Code – 3002)
16.1 Major Exporting Countries
16.1.1 By Value
16.1.2 By Volume
16.2 Major Importing Countries
16.2.1 By Value
16.2.2 By Volume
17 Competitive Landscape
17.1 Market Structure
17.2 Company Profiles
17.2.1 Samsung Biologics
17.2.1.1 Company Overview
17.2.1.2 Product Portfolio
17.2.1.3 Demographic Reach and Achievements
17.2.1.4 Certifications
17.2.2 Amgen Inc.
17.2.2.1 Company Overview
17.2.2.2 Product Portfolio
17.2.2.3 Demographic Reach and Achievements
17.2.2.4 Certifications
17.2.3 Novo Nordisk A/S
17.2.3.1 Company Overview
17.2.3.2 Product Portfolio
17.2.3.3 Demographic Reach and Achievements
17.2.3.4 Certifications
17.2.4 Pfizer Inc.
17.2.4.1 Company Overview
17.2.4.2 Product Portfolio
17.2.4.3 Demographic Reach and Achievements
17.2.4.4 Certifications
17.2.5 Merck & Co., Inc.
17.2.5.1 Company Overview
17.2.5.2 Product Portfolio
17.2.5.3 Demographic Reach and Achievements
17.2.5.4 Certifications
17.2.6 Precision Biologics, Inc.
17.2.6.1 Company Overview
17.2.6.2 Product Portfolio
17.2.6.3 Demographic Reach and Achievements
17.2.6.4 Certifications
17.2.7 F. Hoffmann-La Roche AG
17.2.7.1 Company Overview
17.2.7.2 Product Portfolio
17.2.7.3 Demographic Reach and Achievements
17.2.7.4 Certifications
17.2.8 Others
18 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Biologics Market: Key Industry Highlights, 2018 and 2032
2. Global Biologics Historical Market: Breakup by Source (USD Billion), 2018-2023
3. Global Biologics Market Forecast: Breakup by Source (USD Billion), 2024-2032
4. Global Biologics Historical Market: Breakup by Product Type (USD Billion), 2018-2023
5. Global Biologics Market Forecast: Breakup by Product Type (USD Billion), 2024-2032
6. Global Biologics Historical Market: Breakup by Manufacturing (USD Billion), 2018-2023
7. Global Biologics Market Forecast: Breakup by Manufacturing (USD Billion), 2024-2032
8. Global Biologics Historical Market: Breakup by Disease Category (USD Billion), 2018-2023
9. Global Biologics Market Forecast: Breakup by Disease Category (USD Billion), 2024-2032
10. Global Biologics Historical Market: Breakup by Region (USD Billion), 2018-2023
11. Global Biologics Market Forecast: Breakup by Region (USD Billion), 2024-2032
12. North America Biologics Historical Market: Breakup by Country (USD Billion), 2018-2023
13. North America Biologics Market Forecast: Breakup by Country (USD Billion), 2024-2032
14. Europe Biologics Historical Market: Breakup by Country (USD Billion), 2018-2023
15. Europe Biologics Market Forecast: Breakup by Country (USD Billion), 2024-2032
16. Asia Pacific Biologics Historical Market: Breakup by Country (USD Billion), 2018-2023
17. Asia Pacific Biologics Market Forecast: Breakup by Country (USD Billion), 2024-2032
18. Latin America Biologics Historical Market: Breakup by Country (USD Billion), 2018-2023
19. Latin America Biologics Market Forecast: Breakup by Country (USD Billion), 2024-2032
20. Middle East and Africa Biologics Historical Market: Breakup by Country (USD Billion), 2018-2023
21. Middle East and Africa Biologics Market Forecast: Breakup by Country (USD Billion), 2024-2032
22. Major Importing Countries by Volume (2020)
23. Major Exporting Countries by Volume (2020)
24. Major Importing Countries by Value (2020)
25. Major Exporting Countries by Value (2020)
26. Global Biologics Market Structure
Key Questions Answered in the Report
The global biologics market is projected to grow at a CAGR of 4.1% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach about USD 528.15 billion by 2032.
The market is being driven by increasing research and development activities and the rising demand for microbial expression systems for the treatment of various chronic diseases.
The key trends of the market include the growing prevalence of chronic conditions, efforts to improve the productivity of biologics products, and the robust growth of the healthcare sector.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The leading sources of biologics in the market are microbial source, and mammalian source, among others.
The significant product types of biologics are monoclonal antibodies, vaccines, recombinant proteins, and antisense, RNAi and molecular therapy, among others.
The various manufacturing segments of biologics are outsourced and in-house.
The major types of manufacturing of biologics are outsourced and in-house.
The key players in the global biologics market are Samsung Biologics, Amgen Inc., Novo Nordisk A/S, Pfizer Inc., Merck & Co., Inc., Precision Biologics, Inc., and F. Hoffmann-La Roche AG, among others.
Analyst Review
The global biologics market is driven by the rising demand for microbial expression systems in the treatment of various chronic diseases. Aided by the increasing research activities to enhance the productivity of biologics products, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 4.1%. The market is projected to reach about USD 528.15 billion by 2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By sources, the market is divided into microbial source, and mammalian source, among others. Based on its product types, the biologics industry can be segmented into monoclonal antibodies, vaccines, recombinant proteins, and antisense, RNAi and molecular therapy, among others. On the basis of manufacturing, the industry is bifurcated into outsourced and in-house. By disease categories, the market is segmented into oncology, infectious disease, immunological disorders, cardiovascular disorders, and hematologic disorders, among others. The major regional markets for biologics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Samsung Biologics, Amgen Inc., Novo Nordisk A/S, Pfizer Inc., Merck & Co., Inc., Precision Biologics, Inc., and F. Hoffmann-La Roche AG, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER